Study of LM103 for advanced solid tumors after treatment failure
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests LM103 in people with advanced solid cancers that have not responded to standard treatments or where standard options are not suitable. It mainly focuses on whether LM103 can be safely given and whether it can shrink tumors or help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your expected survival time is at least 6 months
- You can do most daily activities (ECOG performance status 0–1)
- You have an advanced solid tumor (like melanoma, head and neck squamous cell cancer, or soft tissue sarcoma) and standard treatment options have failed or aren’t possible
- Your care team can collect tumor tissue: either a lesion big enough for surgery/biopsy and at least 6 biopsy sites for TILs collection
- You have at least one measurable tumor spot that can be followed on scans (RECIST v1.1)
- Your blood, liver, and kidney tests show enough organ function for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a type of immune cell treatment (TILs) made from your tumor to treat advanced solid cancers. It may help if standard treatments have failed or aren’t an option, but you must be able to provide enough tumor tissue for cell collection.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.